Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maoxia Zheng

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
American Journal of Human Genetics|December 13, 2006
Multipoint linkage-disequilibrium mapping with haplotype-block structureMaoxia Zheng, Mary Sara McPeek
Journal of Biopharmaceutical Statistics|January 13, 2023
Advancing drug development in pediatric oncology, a focus on cancer biology and targeted therapies: iMATRIX platformMarianne Uguen, Magalie Hilton, Mufiza Farid-Kapadia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabineIan E Krop, Patricia LoRusso, Kathy D Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2023
Bevacizumab Alone and in Combination With Irinotecan in Recurrent GlioblastomaHenry S Friedman, Michael D Prados, Patrick Y Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Bevacizumab alone and in combination with irinotecan in recurrent glioblastomaHenry S Friedman, Michael D Prados, Patrick Y Wen, et al.
Neuro-Oncology|May 12, 2011
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumabJeffrey S Wefel, Timothy Cloughesy, James L Zazzali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapyHoward A Burris, Hope S Rugo, Svetislava J Vukelja, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
American Journal of Human Genetics|December 13, 2006
Multipoint linkage-disequilibrium mapping with haplotype-block structureMaoxia Zheng, Mary Sara McPeek
Journal of Biopharmaceutical Statistics|January 13, 2023
Advancing drug development in pediatric oncology, a focus on cancer biology and targeted therapies: iMATRIX platformMarianne Uguen, Magalie Hilton, Mufiza Farid-Kapadia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabineIan E Krop, Patricia LoRusso, Kathy D Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2023
Bevacizumab Alone and in Combination With Irinotecan in Recurrent GlioblastomaHenry S Friedman, Michael D Prados, Patrick Y Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Bevacizumab alone and in combination with irinotecan in recurrent glioblastomaHenry S Friedman, Michael D Prados, Patrick Y Wen, et al.
Neuro-Oncology|May 12, 2011
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumabJeffrey S Wefel, Timothy Cloughesy, James L Zazzali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapyHoward A Burris, Hope S Rugo, Svetislava J Vukelja, et al.
Pageof 1